Carbohydrate-based vaccines: An overview

Methods in Molecular Biology

Volumn 1331, Issue , 2015, Pages 1-10

  Hütter, Julia ^a   Lepenies, Bernd ^a  

^a NONE

Author keywords

Carbohydrates; Glycans; Glycoconjugates; Polysaccharides; Vaccines

Indexed keywords

CARBOHYDRATE; GLYCOCONJUGATE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; MENINGOCOCCUS VACCINE; PNEUMOCOCCUS VACCINE; POLYSACCHARIDE; TYPHOID VACCINE; VACCINE; BACTERIAL VACCINE; BACTERIUM ANTIBODY;

HAEMOPHILUS INFECTION; HUMAN; IMMUNE SYSTEM; INFECTION PREVENTION; MENINGOCOCCOSIS; NONHUMAN; PNEUMOCOCCAL INFECTION; TYPHOID FEVER; VACCINATION; IMMUNOLOGY; PROCEDURES; STREPTOCOCCUS PNEUMONIAE;

ANTIBODIES, BACTERIAL; BACTERIAL VACCINES; CARBOHYDRATES; GLYCOCONJUGATES; HUMANS; PNEUMOCOCCAL INFECTIONS; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

EID: 84959197554     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4939-2874-3_1     Document Type: Chapter

References (70)

1. Plotkin SA (2005) Vaccines: past, present and future. Nat Med 11:S5–S11
2. Pollard AJ, Perrett KP, Beverley PC (2009) Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat Rev Immunol 9:213–220
3. Pulendran B, Ahmed R (2011) Immunological mechanisms of vaccination. Nat Immunol 12: 509–517
4. Hilleman MR (2000) Vaccines in historic evolution and perspective: a narrative of vaccine discoveries. Vaccine 18:1436–1447
5. Rappuoli R, Black S, Lambert PH (2011) Vaccine discovery and translation of new vaccine technology. Lancet 378:360–368
6. Heidelberger M, Avery OT (1923) The Soluble Specific Substance of Pneumococcus. J Exp Med 38:73–79
7. Heidelberger M, Avery OT (1924) The Soluble Specific Substance of Pneumococcus: Second Paper. J Exp Med 40:301–317
8. Ortqvist A (2001) Pneumococcal vaccination: current and future issues. Eur Respir J 18: 184–195
9. Dubos R, Avery OT (1931) Decomposition of the Capsular Polysaccharide of Pneumococcus Type Iii by a Bacterial Enzyme. J Exp Med 54:51–71
10. Avery OT, Dubos R (1931) The Protective Action of a Specific Enzyme against Type Iii Pneumococcus Infection in Mice. J Exp Med 54:73–89
11. Yother J (2011) Capsules of Streptococcus pneumoniae and other bacteria: paradigms for polysaccharide biosynthesis and regulation. Annu Rev Microbiol 65:563–581
12. Mond JJ, Kokai-Kun JF (2008) The multifunctional role of antibodies in the protective response to bacterial T cell-independent antigens. Curr Top Microbiol Immunol 319:17–40
13. Weintraub A (2003) Immunology of bacterial polysaccharide antigens. Carbohyd Res 338: 2539–2547
14. Francis T, Tillett WS (1930) Cutaneous reactions in pneumonia. The development of antibodies following the intradermal injection of type-specific polysaccharide. J Exp Med 52: 573–585
15. Tillett WS, Francis T (1930) Serological Reactions in Pneumonia with a Non-Protein Somatic Fraction of Pneumococcus. J Exp Med 52:561–571
16. Grabenstein JD, Klugman KP (2012) A century of pneumococcal vaccination research in humans. Clin Microbiol Infect 18(Suppl 5): 15–24
17. Landsteiner K (1921) Über heterogenetisches antigen und hapten. XV. Mitteilung über antigene. Biochem Z 119:294–306
18. Davies J, Davies D (2010) Origins and evolution of antibiotic resistance. Microbiol Mol Biol Rev 74:417–433
19. Vliegenthart JF (2006) Carbohydrate based vaccines. FEBS Lett 580:2945–2950
20. Vipond C, Care R, Feavers IM (2012) History of meningococcal vaccines and their serological correlates of protection. Vaccine 30(Suppl 2): B10–B17
21. Caesar NM, Myers KA, Fan X (2013) Neisseria meningitidis serogroup B vaccine development. Microb Pathog 57:33–40
22. Yogev R, Tan T (2011) Meningococcal disease: the advances and challenges of meningococcal disease prevention. Hum Vaccin 7:828–837
23. Morris SK, Moss WJ, Halsey N (2008) Haemophilus influenzae type b conjugate vaccine use and effectiveness. Lancet Infect Dis 8:435–443
24. Shapiro ED, Berg AT (1990) Protective effi- cacy of Haemophilus influenzae type b polysaccharide vaccine. Pediatrics 85:643–647
25. Crump JA, Mintz ED (2010) Global trends in typhoid and paratyphoid Fever. Clin Infect Dis 50:241–246
26. Hessel L, Debois H, Fletcher M et al (1999) Experience with Salmonella typhi Vi capsular polysaccharide vaccine. Eur J Clin Microbiol Infect Dis 18:609–620
27. Barrett DJ (1985) Human immune responses to polysaccharide antigens: an analysis of bacterial polysaccharide vaccines in infants. Adv Pediatr 32:139–158
28. Simon R, Levine MM (2012) Glycoconjugate vaccine strategies for protection against invasive Salmonella infections. Hum Vaccin Immunother 8:494–498
29. Adderson EE (2001) Antibody repertoires in infants and adults: effects of T-independent and T-dependent immunizations. Springer Semin Immunopathol 23:387–403
30. Avci FY, Kasper DL (2010) How bacterial carbohydrates influence the adaptive immune system. Annu Rev Immunol 28:107–130
31. Mond JJ, Lees A, Snapper CM (1995) T cellindependent antigens type 2. Annu Rev Immunol 13:655–692
32. Vos Q, Lees A, Wu ZQ et al (2000) B-cell activation by T-cell-independent type 2 antigens as an integral part of the humoral immune response to pathogenic microorganisms. Immunol Rev 176:154–170
33. Goldblatt D (2000) Conjugate vaccines. Clin Exp Immunol 119:1–3
34. Skinner JM, Indrawati L, Cannon J et al (2011) Pre-clinical evaluation of a 15-valent pneumococcal conjugate vaccine (PCV15- CRM197) in an infant-rhesus monkey immunogenicity model. Vaccine 29:8870–8876
35. Knuf M, Kowalzik F, Kieninger D (2011) Comparative effects of carrier proteins on vaccine- induced immune response. Vaccine 29:4881–4890
36. Heath WR, Carbone FR (2001) Crosspresentation in viral immunity and selftolerance. Nat Rev Immunol 1:126–134
37. Ada G, Isaacs D (2003) Carbohydrate-protein conjugate vaccines. Clin Microbiol Infect 9:79–85
38. Weil-Olivier C, van der Linden M, de Schutter I et al (2012) Prevention of pneumococcal diseases in the post-seven valent vaccine era: a European perspective. BMC Infect Dis 12:207
39. Astronomo RD, Burton DR (2010) Carbohydrate vaccines: developing sweet solutions to sticky situations? Nat Rev Drug Discov 9:308–324
40. Rebeaud F, Bachmann MF (2012) Immunization strategies for Clostridium difficile infections. Expert Rev Vaccines 11:469–479
41. Monteiro MA, Ma Z, Bertolo L et al (2013) Carbohydrate-based Clostridium difficile vaccines. Expert Rev Vaccines 12:421–431
42. Oberli MA, Hecht ML, Bindschädler P et al (2011) A possible oligosaccharide-conjugate vaccine candidate for Clostridium difficile is antigenic and immunogenic. Chem Biol 18: 580–588
43. Martin CE, Broecker F, Oberli MA et al (2013) Immunological evaluation of a synthetic Clostridium difficile oligosaccharide conjugate vaccine candidate and identification of a minimal epitope. J Am Chem Soc 135:9713–9722
44. Cutler JE, Deepe GS Jr, Klein BS (2007) Advances in combating fungal diseases: vaccines on the threshold. Nat Rev Microbiol 5:13–28
45. Cassone A (2013) Development of vaccines for Candida albicans: fighting a skilled transformer. Nat Rev Microbiol 11:884–891
46. Cummings R, Turco S (2009) Parasitic Infections. In: Varki A et al (eds) Essentials of glycobiology, 2nd edn. Cold Spring Harbor (NY), New York
47. Nyame AK, Kawar ZS, Cummings RD (2004) Antigenic glycans in parasitic infections: implications for vaccines and diagnostics. Arch Biochem Biophys 426:182–200
48. van Diepen A, Van der Velden NS, Smit CH et al (2012) Parasite glycans and antibodymediated immune responses in Schistosoma infection. Parasitology 139:1219–1230
49. Colley DG, Bustinduy AL, Secor WE et al (2014) Human schistosomiasis. Lancet 383: 2253–2264
50. Walker DM, Oghumu S, Gupta G et al (2014) Mechanisms of cellular invasion by intracellular parasites. Cell Mol Life Sci 71:1245–1263
51. Schofield L, Hewitt MC, Evans K et al (2002) Synthetic GPI as a candidate anti-toxic vaccine in a model of malaria. Nature 418:785–789
52. Kwon YU, Soucy RL, Snyder DA et al (2005) Assembly of a series of malarial glycosylphosphatidylinositol anchor oligosaccharides. Chemistry 11:2493–2504
53. Hewitt MC, Seeberger PH (2001) Solution and solid-support synthesis of a potential leishmaniasis carbohydrate vaccine. J Org Chem 66:4233–4243
54. Liu X, Siegrist S, Amacker M et al (2006) Enhancement of the immunogenicity of synthetic carbohydrates by conjugation to virosomes: a leishmaniasis vaccine candidate. ACS Chem Biol 1:161–164
55. Vigerust DJ, Shepherd VL (2007) Virus glycosylation: role in virulence and immune interactions. Trends Microbiol 15:211–218
56. Wyatt R, Kwong PD, Desjardins E et al (1998) The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393:705–711
57. Walker LM, Huber M, Doores KJ et al (2011) Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477: 466–470
58. Mouquet H, Scharf L, Euler Z et al (2012) Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. Proc Natl Acad Sci U S A 109:E3268–E3277
59. Kong L, Lee JH, Doores KJ et al (2013) Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. Nat Struct Mol Biol 20:796–803
60. Heimburg-Molinaro J, Lum M, Vijay G et al (2011) Cancer vaccines and carbohydrate epitopes. Vaccine 29:8802–8826
61. Hevey R, Ling CC (2012) Recent advances in developing synthetic carbohydrate-based vaccines for cancer immunotherapies. Future Med Chem 4:545–584
62. Cobb BA, Wang Q, Tzianabos AO et al (2004) Polysaccharide processing and presentation by the MHCII pathway. Cell 117:677–687
63. Avci FY, Li X, Tsuji M et al (2013) Carbohydrates and T cells: a sweet twosome. Semin Immunol 25:146–151
64. Cobb BA, Kasper DL (2005) Zwitterionic capsular polysaccharides: the new MHCIIdependent antigens. Cell Microbiol 7: 1398–1403
65. Gallorini S, Berti F, Mancuso G et al (2009) Toll-like receptor 2 dependent immunogenicity of glycoconjugate vaccines containing chemically derived zwitterionic polysaccharides. Proc Natl Acad Sci U S A 106: 17481–17486
66. Lepenies B, Seeberger PH (2010) The promise of glycomics, glycan arrays and carbohydratebased vaccines. Immunopharmacol Immunotoxicol 32:196–207
67. Verez-Bencomo V, Fernandez-Santana V, Hardy E et al (2004) A synthetic conjugate polysaccharide vaccine against Haemophilus influenzae type b. Science 305:522–525
68. Anish C, Schumann B, Pereira CL et al (2014) Chemical biology approaches to designing defined carbohydrate vaccines. Chem Biol 21:38–50
69. Yang Y, Oishi S, Martin CE et al (2013) Diversity-oriented synthesis of inner core oligosaccharides of the lipopolysaccharide of pathogenic Gram-negative bacteria. J Am Chem Soc 135:6262–6271
70. Cavallari M, Stallforth P, Kalinichenko A et al (2014) A semisynthetic carbohydrate-lipid vaccine that protects against S. pneumoniae in mice. Nat Chem Biol 10:950–956